Nasdaq · Healthcare
Pyxis Oncology, Inc. (PYXS)
As-reported financials and recent SEC filings for Pyxis Oncology, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$13.9M
Net income
$-79.6M
Net margin
—
Diluted EPS
$-1.28
ROE
-149.1%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $13.9M | $16.1M | — | — | — |
| Gross profit | $11.5M | — | — | — | — |
| Operating income | $-84.4M | $-89.5M | $-82.2M | $-123.5M | $-69.7M |
| Net income | $-79.6M | $-77.3M | $-73.8M | $-120.7M | $-76.0M |
| Diluted EPS | $-1.28 | $-1.32 | $-1.85 | $-3.65 | $-2.24 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →8-K2026-07-02
View on EDGAR →SCHEDULE 13G/A2026-07-02
View on EDGAR →1442026-06-30
View on EDGAR →8-K2026-06-15
View on EDGAR →10-Q2026-05-14
View on EDGAR →8-K2026-05-14
View on EDGAR →ARS2026-04-30
View on EDGAR →Largest Healthcare peers
Go deeper on PYXS
Search Pyxis Oncology, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.